Friday, November 21, 2025 10:45:12 AM
Hyperopia, 2023:
There are 2 manufacturing suites which are a total of about 4,000 square feet, but the number or type of cleanrooms, are unknown (to me), and this information wasn’t given in Catapult’s 2023 Manufacturing Report. However, what has been stated in various public documents, is the 1B buildout includes a sterility and QC testing lab, a large Grade C process development lab, and multiple Grade C cleanrooms where the Flaskworks systems will be deployed. Another interesting nugget, according to last month’s 10k, this Grade C process development space will also be used “for future work on next-generation technologies, including as part of collaborations that are under development.”
Me: At this point, the 1B buildout was complete and held C rooms. This is doubly confirmed by Catapult's 2023 Manufacturing Report that reports Advent owning 7 clean rooms, that include "2 Grade B rooms; 3 Grade C rooms; and 2 Grade D rooms". Catapult refers to them as cleanrooms, not suites. And we know that suites can hold several cleanrooms.
2023 10Q report:
The buildout of Phase 1B of the facility, which had begun in 2022, was completed. This included a large new Process Development (PD) lab that helped substantially with the Flaskworks development activities during the remainder of the year. The new PD lab will also be useful for future work on next-generation technologies, including as part of collaborations that are under development.
Me: Since we now know that Advent had 3 C rooms as far back as 2023 in the B1 suite that was just completed,when they were working on continued development of Flaskworks closed system, it makes perfect sense that they would conduct the work in the "large new Processing Development room," in that suite.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
